JNJ - Public offerings

Kenvue Inc. (NYSE:KVUE) ("Kenvue") announced today the pricing of its previously announced secondary underwritten public offering (the "Offering") of 182,329,550 shares of its common stock (the "Shares") at a public offering price of $20.00 per share. The Offering is expected to close on May 17, 2024, subject to the satisfaction or waiver of customary closing conditions. Kenvue is not selling any shares of common stock and will not receive any proceeds from the sale of the Shares in the Offering or from the debt-for-equity exchange (as described below). In connection with the Offering, Johnson & Johnson (NYSE:JNJ) is expected to exchange the Shares for indebtedness of Johnson & Johnson ex

Kenvue Inc. (NYSE:KVUE) ("Kenvue") announced today the launch of a secondary underwritten public offering (the "Offering") of 182,329,550 shares of its common stock (the "Shares"). Kenvue is not selling any shares of common stock and will not receive any proceeds from the sale of the Shares in the Offering or from the debt-for-equity exchange (as described below). In connection with the Offering, Johnson & Johnson (NYSE:JNJ) is expected to exchange 182,329,550 shares of Kenvue's common stock for indebtedness of Johnson & Johnson expected to be held by Goldman Sachs & Co. LLC and J.P. Morgan (collectively, the "Selling Shareholders"). Following the debt-for-equity exchange, if consummated,

Company expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and Adjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine Company expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of 12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at the mid-point Company reduced outstanding share count by approximately 191 million; 2023 guidance reflects only a partial-year benefit of approximately 73.5 million shares or $0.28 benefit to EPS Company secured $13.2 billion in cash proceeds from the Kenvue deb

Separation enhances Company focus on Pharmaceutical and MedTech Research & Development to deliver innovative and differentiated health outcomes Johnson & Johnson shareholders can exchange all, some or none of their shares of Johnson & Johnson common stock for shares of Kenvue Provides Johnson & Johnson shareholders with option for a tax-free exchange for U.S. Federal income tax purposes Johnson & Johnson (NYSE:JNJ) today announced its intention to split-off at least 80.1% of the shares of Kenvue Inc. (NYSE:KVUE) ("Kenvue") through an exchange offer. Kenvue, formerly Johnson & Johnson's Consumer Health business, completed its initial public offering ("IPO") in May 2023. Through the pla

2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%* Earnings per share (EPS) of $1.96 increasing 8.9% and adjusted EPS of $2.80 increasing by 8.1%* Company is increasing 2023 full-year guidance midpoints for adjusted operational sales excluding COVID-19 Vaccine and adjusted operational EPS Johnson & Johnson intends to "split off" Kenvue shares through an exchange offer as the form of its next step in the separation, subject to market conditions Johnson & Johnson (NYSE:JNJ) today announced results for second-quarter 2023. "Our robust pe

Kenvue Inc. (NYSE:KVUE) ("Kenvue") the world's largest pure-play consumer health company by revenue, today announced the closing of its initial public offering ("IPO") of 198,734,444 shares of its common stock at a price to the public of $22.00 per share, including the underwriters' full exercise of their option to purchase 25,921,884 shares to cover over-allotments. Shares of Kenvue's common stock began trading on the New York Stock Exchange under the symbol "KVUE" on May 4, 2023. As of the closing of the IPO, Johnson & Johnson (NYSE:JNJ) owns approximately 89.6% of the total outstanding shares of Kenvue common stock. Johnson & Johnson has publicly stated that it has an intention to disp

Johnson & Johnson (NYSE:JNJ) and Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue's upsized initial public offering ("IPO") of 172,812,560 shares of Kenvue's common stock at a price to the public of $22.00 per share. In addition, Kenvue has granted the underwriters a 30-day option to purchase up to an additional 25,921,884 shares of its common stock to cover over-allotments, if any. Kenvue's common stock has been approved for listing on the New York Stock Exchange under the symbol "KVUE" and is expected to begin trading on May 4, 2023. The IPO is expected to close on May 8, 2023, subject to the satisfaction or waiver of customary

Johnson & Johnson (NYSE:JNJ) today announced that Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering ("IPO") of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol "KVUE." After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenv

Johnson & Johnson (NYSE:JNJ) today announced that Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, priced an offering of the following series of senior unsecured notes in an aggregate principal amount of $7.75 billion (each series of notes collectively, the "Notes"): Principal Coupon Maturity Date $750,000,000 5.500% Senior Notes due 2025 $750,000,000 5.350% Senior Notes due 2026 $1,000,000,000 5.050% Senior Notes due 2028 $1,000,000,000 5.000% Senior Notes due 2030 $1,250,000,000 4.900% Senior Notes due 2033 $750,000,000 5.100% Senior Notes due 2043 $1,500,000,000 5.050% Senior Note

VICTORIA, BC, May 3, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed industry veteran Bruce Cousins as the Company's new President and Chief Financial Officer. Mr. Cousins' appointment is effective May 3, 2021. The combined role of President and CFO reflects the broader scope of the new roles' operating and corporate responsibilities, as well as oversight of financial management and public markets reporting. Consistent with the appointment, the Company's current CFO Alex Rothwell will remain full-time with the Com

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Investments continued flowing into the psychedelic medicine sector this year and will likely continue in 2021 as mental illness cases rise across the globe. The World Health Organization (WHO) estimates that 700 million cases of mental and neurological disorders are reported annually, accounting for 13% of global disease burden. Of course, these are only reported cases, so the number is likely much higher and will likely rise further due to the ongoing health crisis. Luckily, growing awareness around mental illness has led to a slew of research and development for effective novel treatments to help combat the growing mental health crisis. Psychedeli

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2020, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $172,889 for the three months ended September 30, 2020, compared with revenue of $234,977 for the three months ended September 30, 2019. Revenue from SIAscopy® of $74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020. Revenue from the Company's therapeutic laser line of $98,603 was a decrease from $177,436 in the prior year period, but $